Project: COMPETE2030-FEDER-00788900

Project name:	FIREGENS - Fibrotic Interstitial lung diseases Reclassifi cation through Environmental and Genetic Studies
Project code:	COMPETE2030-FEDER-00788900
Intervention Region:	Norte
Proposing institution/Lead promoter/Coordinating entity:	Faculdade de Medicina da Universidade do Porto
Partner(s)/Co-promoter(s)/Participating institution(s):	Instituto de Investigação e Inovação em Saúde da Universidade do Porto
Date of approval:	2025-05-08
Start date:	2025-09-01
Completion date:	2028-08-30

Objectives, activities and expected/achieved results

The FIREGENS proposal envisions to contribute for the advance of precision medicine in ILD field, laying the foundations for individualized preventive and therapeutic approaches. Specifically, we aim to accomplish the following objectives:
1.Comprehensively characterize individuals beyond the scope of disease etiopathogenesis. Expand our understanding of endotypes and phenotypes to encompass genetic and environmental risk factors (addressed in Section 8 - Task 1);
2.Implement a non-invasive testing method to confirm antigen sensitization. To improve HP diagnosis and to investigate the impact of occult environmental factors in the pathophysiology of other fibrotic ILDs, we will develop an optimized test using as readout the activation of a fungal-specific T cell response (Task 2);
3.Develop a treatable traits approach in fi brotic ILDs. This strategy combines both modifiable factors, such as airborne exposure (Tasks 1-2), and measurable biomarkers (Task 3), that inform prognosis and treatment response, intended to enable adaptable therapeutic recommendations as the disease progresses;
4.Elaborate a predictive model to improve diagnosis and prognosis defi nition. Upon achieving the aforementioned objectives as demonstrated by the outcomes of Tasks 1-3, we aim to enhance the accuracy of ILD classification through nationwide validation. This effort particularly targets cases with overlapping features and unclassifi able ILDs, encompassing the risk of disease progression (Task 4).

Recommend this page Top

Facebook Linkedin Instagram TikTok Youtube Twitter / X

Privacy Policy | Personal Data Protection Policy | Digital Image Capture and Dissemination Policy | Whistleblowing | Electronic Yellow Book